allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

BIOLOGICAL3 trials

Sponsors

University of Alabama at Birmingham, Northwestern University, Milton S. Hershey Medical Center

Conditions

LeukemiaLymphomaMultiple Myeloma and Plasma Cell Neoplasm

Phase 1

Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

Milton S. Hershey Medical CenterLymphoma

Start: 2000-04-30Updated: 2013-12-18

Immunotherapy for Lymphoproliferative Diseases Associated With Epstein-Barr Virus in Patients Who Have Undergone Organ Transplants

WithdrawnNCT00002956

University of Alabama at BirminghamLeukemia, Lymphoma

Start: 1996-11-30End: 2002-02-28Updated: 2016-03-21

Phase 2

Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation

CompletedNCT00005606

Northwestern UniversityLeukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm

Start: 2000-02-29End: 2003-09-30Updated: 2012-06-06